HR Execs on the Move

Social Interest Solutions

www.oneeapp.org

 
Social Interest Solutions is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Oakland, CA. To find more information about Social Interest Solutions, please visit www.oneeapp.org
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.oneeapp.org
  • 1333 Broadway Ste 1020
    Oakland, CA USA 94612-1926
  • Phone: 510.834.1300

Executives

Name Title Contact Details

Similar Companies

Donell Super Skin

Donell Super Skin is a Bardstown, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivano Physicians

Nivano Physicians is an Independent Physician Association (IPA) that operates within Sacramento and surrounding counties. They are committed to advocating for the Medi-Cal community and ensuring that managed healthcare is manageable.

SIMMS AND MCIVOR

SIMMS AND MCIVOR is a Branchburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vested Health

Vested Health is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.